Katalog Plus
Bibliothek der Frankfurt UAS
Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.
Dieses Ergebnis aus BASE kann Gästen nicht angezeigt werden.  Login für vollen Zugriff.

Reversal of Doxorubicin Resistance in Human Breast Adenocarcinoma (MCF-7) Cells by Liposomal Monensin

Title: Reversal of Doxorubicin Resistance in Human Breast Adenocarcinoma (MCF-7) Cells by Liposomal Monensin
Authors: Sachdeva, Mandip S.
Contributors: FLORIDA AGRICULTURAL AND MECHANICAL UNIV TALLAHASSEE
Source: DTIC
Publication Year: 2005
Collection: Defense Technical Information Center: DTIC Technical Reports database
Subject Terms: Medicine and Medical Research; Pharmacology; BREAST CANCER; LIPOSOMES; CYTOTOXINS; DRUGS; APOPTOSIS; MAMMARY GLANDS; RESISTANCE(BIOLOGY); DRUG TOLERANCE; SML(STEALTH MONENSIN LIPOSOMES); MCF-7 CELLS; DOXORUBICIN
Description: We have previously demonstrated that stealth monensin liposomes (SML) prepared by pH-gradient method enhance the cytotoxicity of doxorubicin by a factor of 16.5 in MCF-7/dox cells. There was increase in MDR-1 and MRP-1 mRNA expression as a result of doxorubicin treatment, which was lowered by combination with SML. In the present study, enhancement of cytotoxic drugs by SML was reinvestigated. It showed that paclitaxel, etoposide and doxorubicin showed 2.8, 5.6 and 16.5 fold increase in cell kill in combination with SML. Caspase-3 assay to confirm apoptosis showed that, doxorubicin increased caspase-3 activity over control, but in combination with SML the activity was further increased by 2.1 fold. Fluorescence studies indicated that doxorubicin uptake was increased as a result of SML treatment. Also our studies indicated that the SML treatment lowered the efflux of doxorubicin from MCF-7/dox cells. Finally in vivo animal experiments were conducted where nulnu mice were xenografted with MCF-7 cells. A group of animals received doxorubicin Smg/kg i.v., while another group received SML (10-6 M) + doxorubicin treatments. Our results demonstrated that there were no significant differences between doxorubicin and SML +doxorubicin treated mice for their tumor inhibition.
Document Type: text
File Description: text/html
Language: English
Relation: http://www.dtic.mil/docs/citations/ADA443420
Availability: http://www.dtic.mil/docs/citations/ADA443420; http://oai.dtic.mil/oai/oai?&verb=getRecord&metadataPrefix=html&identifier=ADA443420
Rights: Approved for public release; distribution is unlimited.
Accession Number: edsbas.A1363235
Database: BASE